OSR Health, Inc. (OSRHW) shareholders
OSRHWOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as OSRH
$0.01+0.00 (0.00%)
Close on Oct 19, 2026Market cap $325.06KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
3M
Shares held, 13F filers
Institutional holders
18
4 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kuk Hyoun Hwang Joint filing with Bellevue Capital Management LLC (87.70%), Bellevue Global Life Science Investors, LLC (58.40%) and 1 more | 2,035,000 | 87.70% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OSRHW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Toronto Dominion Bank | 604,164 | – | $32.02K | −7,783 | 0.00% |
| Polar Asset Management Partners Inc. | 360,000 | – | $19.08K | – | 0.00% |
| Periscope Capital Inc. | 299,900 | – | $15.90K | – | 0.00% |
| Clear Street Group Inc. | 291,824 | – | $15.47K | −259 | 0.00% |
| LMR Partners LLP | 253,001 | – | $13.41K | – | 0.00% |
| Rivernorth Capital Management, LLC | 250,000 | – | $7.63K | – | 0.00% |
| Saba Capital Management, L.P. | 250,000 | – | $13.26K | – | 0.00% |
| D. E. Shaw & Co., Inc. | 150,000 | – | $7.95K | – | 0.00% |
| Wolverine Asset Management LLC | 111,585 | – | $5.91K | – | 0.00% |
| Centiva Capital, LP | 100,000 | – | $5.30K | – | 0.00% |
| Boothbay Fund Management, LLC | 95,040 | – | $30.06K | – | 0.00% |
| Mint Tower Capital Management B.V. | 75,000 | – | $4.00K | – | 0.00% |
| Aristeia Capital LLC | 73,341 | – | $3.89K | – | 0.00% |
| Flow Traders U.S. LLC | 24,173 | – | $1.00K | +443 | 0.00% |
| Susquehanna International Group, Llp | 21,458 | – | $1.14K | New | 0.00% |
| Hrt Financial LP | 19,146 | – | $1.00K | New | 0.00% |
| Two Sigma Securities, LLC | 17,891 | – | $948 | New | 0.00% |
| UBS Group AG | 1,347 | – | $71 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 18 | 3M | 4 / 1 | 2 / 2 | 0M | 0M |
| Q1 2026 | 16 | 3M | 0 / 1 | 1 / 1 | 0M | 0M |
| Q4 2025 | 17 | 3M | 0 / 1 | 3 / 2 | 0M | 0M |
| Q3 2025 | 20 | 3M | 2 / 2 | 1 / 2 | 0M | 0M |
| Q2 2025 | 21 | 4M | 4 / 2 | 4 / 3 | 1M | 0M |
| Q1 2025 | 20 | 3M | 20 / 0 | 0 / 0 | 3M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Kuk Hyoun Hwang | President and CEO, Director, 10% owner | 24,317,738 | Feb 19, 2025 |
| Yeiseok Kim | Chief Operating Officer | 24,699 | Apr 16, 2026 |
| Sang Harry Kim | See Remarks | – | Feb 21, 2025 |
| Gihyoun Bang | Chief Financial Officer | – | Feb 20, 2025 |
| Reto Kaspar Fierz | Director | – | Oct 24, 2025 |
| Joong Myung Cho | Director | – | Feb 21, 2025 |
| Alcide Barberis | Director | – | Feb 21, 2025 |
| Hyuk Joo Jee | Director | – | Feb 20, 2025 |
| Capital Management LLC Bellevue | 10% owner | 3,123,970 | Feb 19, 2025 |
| Europe AG BCM | 10% owner | 7,531,634 | Feb 19, 2025 |
| Global Life Science Investors LLC Bellevue | 10% owner | 2,043,500 | Feb 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2025 | Other | +43,000 | – | – | 2,043,500 |
| Kuk Hyoun Hwang President and CEO, Director, 10% owner | Feb 14, 2025 | Other | +7,531,634 | – | – | 9,575,134 |
| Kuk Hyoun Hwang President and CEO, Director, 10% owner | Feb 14, 2025 | Other | +3,123,970 | – | – | 12,699,104 |
| Kuk Hyoun Hwang President and CEO, Director, 10% owner | Feb 14, 2025 | Other | +43,000 | – | – | 2,043,500 |
| Global Life Science Investors LLC Bellevue 10% owner | Mar 23, 2023 | Other | −20,000 | – | – | 2,000,500 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Mar 23, 2023 | Other | −20,000 | – | – | 2,000,500 |
| David Jin Yoo Chief Financial Officer | Mar 23, 2023 | Award | +20,000 | – | – | 20,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 21, 2023 | Other | −4,500 | – | – | 2,020,500 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 21, 2023 | Other | +225,000 | – | – | 2,025,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 21, 2023 | Other | −4,500 | – | – | 2,020,500 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 21, 2023 | Other | +225,000 | – | – | 2,025,000 |
| Hosun Euh Director | Feb 14, 2023 | Award | +20,000 | – | – | 20,000 |
| Steven Reed Director | Feb 14, 2023 | Award | +20,000 | – | – | 20,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −30,000 | – | – | 1,370,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −225,000 | – | – | 1,400,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,625,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Award | +430,000 | $10.00 | $4.30M | 1,800,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,665,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,685,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,705,000 |
| Kuk Hyoun Hwang Chief Executive Officer, Director, 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,645,000 |
| Jin Whan Park Director | Feb 14, 2023 | Award | +20,000 | – | – | 20,000 |
| Rad Roberts Director | Feb 14, 2023 | Award | +20,000 | – | – | 20,000 |
| In Chul Chung Director | Feb 14, 2023 | Award | +20,000 | – | – | 20,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,645,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −30,000 | – | – | 1,370,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −225,000 | – | – | 1,400,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,625,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Award | +430,000 | $10.00 | $4.30M | 1,800,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,665,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,685,000 |
| Global Life Science Investors LLC Bellevue 10% owner | Feb 14, 2023 | Other | −20,000 | – | – | 1,705,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
81.8
At 0M shares a day
Change since last report
-1.5%
From 0M shares
Short volume, 20 days
65.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of OSR Health's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,762 shares on Aug 18, 2026 over the last 90 days.